AI-Integrated Modeling & Simulation for Drug Development
APLUS Simulation is a next-generation pharmacometrics company integrating advanced Modeling & Simulation (M&S) with AI-driven technologies to transform drug development. We help pharmaceutical and biotechnology companies translate complex biological data into quantitative insights for clinical decision-making.
By combining pharmacometrics expertise, mechanistic modeling, and artificial intelligence, APLUS Simulation enables more accurate prediction of drug exposure, efficacy, and safety in humans. Our mission is to accelerate drug development through human-relevant, data-driven modeling technologies, and ultimately contribute to improving global health outcomes for patients worldwide.
Why APLUS Simulation
APLUS Simulation brings together scientific expertise and technology innovation to enable clinical pharmacology-driven, model-informed decision-making in drug development.
Deep Pharmacometrics Expertise
Founders and scientists with more than a decade of hands-on modeling experience.
We apply pharmacometrics as a quantitative framework for clinical decision-making, not just data analysis.
Our modeling approaches are designed to address modality-specific complexity while maintaining a unified decision-making framework.
Clinical Pharmacology & Decision-Focused Modeling
We integrate clinical pharmacology principles with modeling & simulation to support:
• First-in-human (FIH) dose selection
• Dose optimization and regimen design
• Exposure–response analysis
• Clinical trial strategy and design
Our models are built to directly inform development decisions and support regulatory submissions.
AI + Mechanistic Modeling Integration
Combining machine learning with pharmacometric and mechanistic modeling approaches to enhance prediction accuracy, scalability, and speed.
Regulatory Experiences
Extensive experience supporting global regulatory submissions, including FDA and EMA modeling packages, ensuring alignment with regulatory expectations.